Contribution of Caspase(s) to the Cell Cycle Regulation at Mitotic Phase by Hashimoto, Toshiaki et al.
Contribution of Caspase(s) to the Cell Cycle Regulation at
Mitotic Phase
Toshiaki Hashimoto, Ushio Kikkawa, Shinji Kamada*
Biosignal Research Center, Kobe University, Nada-ku, Kobe, Japan
Abstract
Caspases have been suggested to contribute to not only apoptosis regulation but also non-apoptotic cellular
phenomena. Recently, we have reported the involvement of caspase-7 to the cell cycle progression at mitotic phase by
knockdown of caspase-7 using small interfering RNAs and short hairpin RNA. Here we showed that chemically
synthesized broad-spectrum caspase inhibitors, which have been used to suppress apoptosis, prevented the cell
proliferation in a dose-dependent manner, and that the subtype-specific peptide-based caspase inhibitor for caspase-3
and -7, but not for caspase-9, inhibited cell proliferation. It was also indicated that the BIR2 domain of X-linked
inhibitor of apoptosis protein, functioning as an inhibitor for caspase-3 and -7, but not the BIR3 domain which plays as
a caspase-9 inhibitor, induced cell cycle arrest. Furthermore, flow cytometry revealed that the cells treated with
caspase inhibitors arrested at G2/M phase. By using HeLa.S-Fucci (fluorescent ubiquitination-based cell cycle indicator)
cells, the prevention of the cell proliferation by caspase inhibitors induced cell cycle arrest at mitotic phase
accompanying the accumulation of the substrates for APC/C, suggesting the impairment of the APC/C activity at the
transition from M to G1 phases. These results indicate that caspase(s) contribute to the cell cycle regulation at mitotic
phase.
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Introduction
Caspase is a family of cysteine proteases that are required for
cytokine maturation and apoptosis execution [1–3]. In mammals,
caspase-1, -4, and -5, which have a large prodomain and cleave
the procytokines, are referred to as inflammatory caspases.
Another group of caspases with a large prodomain including
caspase-2, -8, -9, and -10 are termed as the initiator caspases of
apoptosis, whereas the enzymes with a short prodomain
comprising caspase-3, -6, and -7 are the effector caspases of
apoptosis. The effector caspases are activated through proteolytic
processing catalyzed by the initiator caspases. On the other hand,
the inhibitor of apoptosis proteins (IAPs) are identified as the
endogenous inhibitors for apoptosis, and eight IAPs have been
thus far isolated in mammals [4,5]. They share a conserved region
known as the baculovirus IAP repeat (BIR) domain. XIAP is one
of IAPs, which contains three distinct BIR domains and a RING
finger domain, and binds directly to caspase-3, -7, and -9 to inhibit
their protease activity.
Cell cycle is controlled by the ubiquitin-mediated proteolysis
of the key regulators [6–9]. Two major classes of ubiquitin
ligases, the SKP1-CUL1-F-box-protein (SCF) complex and the
anaphase-promoting complex/cyclosome (APC/C), play central
roles in the cell cycle regulation through the ubiquitination of
various cell cycle regulators. The SCF complex functions from
late G1 phase to early M phase, whereas APC/C is active from
anaphase to the end of G1 phase. There are two activators for
APC/C, cell division cycle 20 (Cdc20) and Cdh1, which bind
with APC/C and recognize respective substrate proteins. APC/
C
Cdc20 targets securin and cyclin B1 for their destruction, and
promotes sister chromatid separation. APC/C
Cdh1 facilitates
exit from M phase and maintains G1 phase by mediating the
degradation of a variety of substrates including PLK1, cyclin B1,
and geminin.
Recently, it has been proposed that initiator and effector
caspases of apoptosis are required for non-apoptotic functions [10–
15]. Concerning caspase-3, an active caspase-3 fragment is
immunostained in the proliferative region in rat brain [16],
caspase-3 is upregulated just prier to mitosis [17], and the
treatment with a caspase-3 inhibitor induces cell death at late
mitosis [18]. Caspase-8 is pointed out to play an essential role in
the development and activation of immune cells [15,16]. In
addition, the activity of caspase-3, -7, -8, and -9 is elevated in some
tumor cells [19–21]. We have recently reported a possible
involvement of caspase-7 to the cell cycle progression at mitosis
[22]. The clear evidence, however, has not been available for the
role of caspases in the regulation of cell proliferation.
In the present study, we showed the contribution of caspase(s) to
the regulation of cell proliferation by the application of the
peptide-based caspase inhibitors and the expression of the BIR
domains of XIAP in the cultured mammalian cancer cells.
Furthermore, it was shown that the inhibition of cell proliferation
by caspase inhibitors was induced by the failure of the APC/C
regulation at the transition from M to G1 phases.
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Peptide-based broad-spectrum caspase inhibitors
prevented cell proliferation
Caspases are pointed out to contribute to the regulation of cell
proliferation [10,11,15], and we have recently reported that
caspase-7 has a novel function in the progression of mitosis by
using small interfering RNAs (siRNAs) and short hairpin RNA
(shRNA) directed towards caspase-7 [22]. It has been unclear,
however, whether the inhibition of caspase activities prevents cell
proliferation. Therefore, we examined the effects of peptide-based
caspase inhibitors on cell proliferation. Cell-permeant broad-
spectrum caspase inhibitors, Z-Asp-CH2-DCB and Boc-As-
p(Obzl)-CMK, are dissolved in DMSO to be added to the culture
medium. We first determined the highest concentration of DMSO
that could be added to the culture medium without affecting
proliferation, since DMSO is toxic to cells. DMSO at 3% had no
significant effect on cell proliferation of HepG2 cells and the
compound at 0.6% was inert for HeLa and Jurkat cells (data not
shown). Therefore, DMSO at these concentrations was used for
each cell line as a vehicle for the reagents in the following
experiments. Broad-spectrum caspase inhibitors prevented prolif-
eration of HepG2, HeLa, and Jurkat cells in a dose-dependent
manner, with complete inhibition at the highest concentrations
(Figure 1A), suggesting that caspase activities are required for
proliferation in HepG2, HeLa, and Jurkat cells.
Next, we set out to clarify which caspase is essential for cell
proliferation by using subtype-specific cell-permeant caspase
inhibitors, in which each inhibitor peptide was fused to the
hydrophobic region of the signal peptide of Kaposi fibroblast
growth factor (K-FGF) at its N-terminal end to confer cell
permeability: Ac-AAVALLPAVLLALLAP-DEVD-CHO (cas-
pase-3 and -7 inhibitor), -IETD-CHO (caspase-8 inhibitor), and
-LEHD-CHO (caspase-9 inhibitor). The inhibitor for caspase-3
and -7 was most effective for preventing proliferation of HepG2
cells (Figure 1B). The caspase-8 inhibitor also attenuated
proliferation of HepG2 cells but less effectively than the caspase-
3 and -7 inhibitor, and the caspase-9 inhibitor had only a marginal
effect. It is less possible that the inhibition of cell proliferation is
due to the toxic effect of the signal peptide of K-FGF, because the
caspase-9 inhibitor having the peptide did not show significant
growth suppression. The results employing the peptide-based
caspase inhibitors indicate that caspase-3 and/or caspase-7 plays
an essential role in cell proliferation, and that caspase-8, but not
Figure 1. Peptide-based caspase inhibitors prevent cell proliferation. A) The effects of broad-spectrum caspase inhibitors on cell
proliferation. HepG2, HeLa, and Jurkat cells were cultured in the presence of broad-spectrum caspase inhibitors as indicated. B) The effects of
subtype-specific caspase inhibitors on cell proliferation. HepG2 cells were cultured in the presence of subtype-specific caspase inhibitors as indicated.
Cell viability was determined by WST-1 assay. DMSO-treated cells were used as a control.
doi:10.1371/journal.pone.0018449.g001
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or -7.
Overexpression of XIAP-BIR2, but not XIAP-BIR3,
prevented cell proliferation
To further explore the role of caspases in cell proliferation, we
examined the effects of XIAP, which inhibits caspase activities
through a different mode of action from that of the peptide-based
inhibitors [23,24]. XIAP has been suggested to inhibit apoptosis
through mechanisms independent of its binding ability to caspases
[25–27], but, in practice, the BIR2 domain with the linker region
(amino acids 124 to 237) and the BIR3 domain (amino acids 252
to 350) suppress the protease activity of caspase-3 and -7 [28] and
caspase-9 [24], respectively. Therefore, we first established a
monitor system to visualize the recombinant XIAP protein as well
as chromatin by transiently introducing XIAP fused to DsRed-
monomer in HeLa-H2B-GFP cells stably expressing histone H2B-
GFP fusion protein [29]. The expression of XIAP and the
structure of chromatin were monitored as the fluorescence of
DsRed and GFP, respectively, by time-lapse fluorescence
microcopy (Figure 2 and Video S1). To make use of XIAP as
the subtype-specific caspase inhibitors in relation to cell prolifer-
ation, we constructed the BIR2 domain with the linker region
fused to DsRed-monomer (DsRed-XIAP-BIR2-Wt) and the BIR3
domain fused to DsRed-monomer (DsRed-XIAP-BIR3-Wt) as a
caspase-3 and -7 inhibitor and caspase-9 inhibitor, respectively
(Figures 2A and B). DsRed-expressing cells were classified into
three types during the observation for 24 hours (Figure 2C and
Videos S1, S2, S3, S4, S5): type I cells, which divided normally
into two nuclei, representing proliferating cells; type II cells, which
had condensed and fragmented nuclei, representing apoptotic
cells; type III cells, which had condensed but not fragmented
nuclei, representing proliferation-arrested cells. Cells overexpress-
ing DsRed-monomer had 60.8% type I, 31.4% type II and 7.8%
type III cells, indicating that more than half of the cells expressing
DsRed were proliferating and that DsRed itself has only a weak
cytotoxicity. The expression of DsRed-XIAP-BIR2-Wt and
DsRed-XIAP-BIR3-Wt decreased apoptosis, 8.7 and 23.7% type
II cells, possibly through inhibition of caspase-3 and -7 and
caspase-9 activities, respectively. Importantly, the cells expressing
DsRed-XIAP-BIR2-Wt showed a decrease of the proliferating
cells (type I) and an increase of proliferation-arrested cells (type
III), 39.1 and 61.8% differences with that of the cells expressing
DsRed, respectively. The expression of DsRed-XIAP-BIR3-Wt,
however, had little effect on cell proliferation. It is reported that
the mutants of XIAP, D148A/E219R/H223V in BIR2 [28] and
E314S in BIR3 [30], cannot inhibit caspase-3 or -7 and caspase-9,
respectively. These mutations abolished not only the inhibition of
apoptosis but also the changes of the numbers of the proliferating
and proliferation-arrested cells in transfected HeLa-H2B-GFP
cells. These results indicate that the activity of caspase-3 and/or
caspase-7, but not caspase-9, is necessary for cell proliferation,
which are consistent with those obtained by the cell-permeant
peptide-based caspase inhibitors as shown in Figure 1B.
Peptide-based caspase inhibitor induced cell cycle arrest
at G2/M phase
To clarify the roles of caspase(s) in the cell cycle progression, the
flow cytometric analysis was carried out using HeLa cells treated
with the caspase inhibitor. HeLa cells treated with DMSO, Z-Asp-
CH2-DCB, or nocodazole for 25 hours were analyzed with flow
cytometry to determine the cell cycle profiles (Figure 3). Although
most of nocodazole-treated cells were accumulated in M phase,
consistent with the ability of nocodazole to disrupt microtubules,
the caspase inhibitor-treated cells showed an increase of cells at G1
and G2/M phases as compared with the DMSO-treated cells.
These results suggest that caspase inhibition induces cell cycle
arrest at G1 and G2/M phases, and that caspase(s), that is
necessary for the cell cycle progression, plays a role, at least in part,
around G2/M phase.
Peptide-based caspase inhibitor impaired the transition
from M to G1 phases through inhibiting APC/C
To analyze the molecular basis for the effects of caspase
inhibition during the cell cycle progression, HeLa.S-Fucci cells
were used, which express monomeric Kusabira-Orange 2
(mKO2) and monomeric Azami-Green 1 (mAG1) fused to the
ubiquitination domains of Cdt1 and geminin, respectively [31].
Since Cdt1 and geminin are the direct substrates of SCF
Skp2 and
APC/C
Cdh1 complexes, respectively, the level of Cdt1 is highest
at G1 phase whereas geminin is prominent during S, G2,a n dM
phases [32]. Therefore, the cell nuclei of HeLa.S-Fucci cells
during the cell cycle are labeled with orange of mKO2 fused to
the ubiquitination domain of Cdt1 in G1 phase and green of
mAG1 fused to the ubiquitination domain of geminin in S, G2,
and M phases. We monitored the morphology of cells and the
color of cell nuclei of HeLa.S-Fucci cells after the treatment with
Z-Asp-CH2-DCB with the time-lapse fluorescence microscope for
48 hours (Figure 4A and Videos S6 and S7). Although the control
cells treated with DMSO proliferated normally with oscillations
in the fluorescence color changes (Figure 4A and Video S6), the
number of caspase inhibitor-treated cells did not increase and a
large fraction of cells showed the round shape with a yellow
fluorescence (Figure 4A and Video S7). To further analyze the
effects of the caspase inhibitor on the cell cycle progression at
mitotic phase, ten mitotic cells which show a round shape with a
green fluorescence were randomly picked up from the cells
treated with DMSO (#1t o#10 in Figure 4A, upper left) and Z-
Asp-CH2-DCB (#11 to #20 in Figure 4A, upper right), and the
progression of mitotic phase of each cell was shown at intervals of
30 minutes for 5 hours (Figure S1). During the normal cell cycle
progression from M phase to G1 phase, mKO2 fused to the
ubiquitination domain of Cdt1 appeared after the disappearance
of mAG1 fused to the ubiquitination domain of geminin and the
execution of cytokinesis. Although 9 out of 10 cells treated with
DMSO (#1–7, 9, and 10 in Figure S1) transited from M phase to
G1 phase within 2.5 hours, a half of the cells treated with Z-Asp-
CH2-DCB (#13, 14, 17, 18, and 20 in Figure S1) seemed to stay
in M phase even at 5 hours later because these cells still showed a
round shape. Surprisingly, 4 out of 5 cells (#14, 17, 18, and 20 in
Figure S1) had a yellow fluorescence indicating the presence of
both mKO2 and mAG1 fluorescent proteins in cells. To further
confirm the coexistence of these fluorescent proteins in cells, the
merged images of ten mitotic cells at 5 hours after the treatment
with the caspase inhibitor (#11–20 in Figure S1) were shown
with phase contrast and fluorescence of mAG1 and mKO2
(Figure 4B). The cells (#14, 17, 18, and 20) coexpressed both
fluorescent proteins, suggesting that the failure of the cell cycle
progression from M phase to G1 phase in the cells treated with
the caspase inhibitor was caused by missing the activity of APC/
C
Cdh1 which is responsible for destruction of mAG1 fused to the
ubiquitination domain of geminin at the transition from M phase
to G1 phase.
If this is the case, target proteins for APC/C
Cdh1 may be
accumulated after treatment with caspase inhibitors. Therefore,
we analyzed the protein levels of the substrates for APC/C and
SCF complexes (Figure 5). The substrates for APC/C accumulat-
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ubiquitination domain of geminin, however, the protein levels of
the substrates for SCF including p27, cyclin E, and mKO2 fused
to the ubiquitination domain of Cdt1 did not change. These results
suggest that the caspase inhibition attenuates the APC/C activities
and leads the cells to arrest at mitotic phase.
Discussion
We report here that the inhibition of caspase(s) resulted in the
prevention of cell proliferation through cell cycle arrest at G1 and
G2/M phases. The broad-spectrum caspase inhibitors, Z-Asp-
CH2-DCB and Boc-Asp(Obzl)-CMK, were needed relatively at
Figure 2. Overexpression of XIAP-BIR2, but not XIAP-BIR3, inhibits cell proliferation. A) Diagrams showing the constructions of DsRed-
XIAP-BIRs expression plasmids and the structure of XIAP with the positions of the point mutations. Mutated amino acid residues are indicated by
arrowheads. B) Expression of DsRed and DsRed-XIAP-BIRs fusion proteins in 293T cells. 293T cells were transiently transfected with DsRed or each
DsRed-XIAP-BIRs expression plasmid as indicated. At 18 hour after transfection, cells were harvested and lysates were subjected to immunoblot
analysis with the anti-DsRed antibody. C) The effects of overexpression of DsRed-XIAP-BIRs on cell proliferation. HeLa-H2B-GFP cells were seeded at a
density of 1610
5 cells per 35-mm glass bottom dish and incubated for 12 hours. Cells were transfected with DsRed or each DsRed-XIAP-BIRs
expression plasmid as indicated and further incubated for 24 hours. Then, cells were observed with the time-lapse fluorescence microscope at 15-
minute intervals for 24 hours (see Videos S1, S2, S3, S4, S5). The observation indicated that DsRed-positive cells were divided into three types of cells;
type I, normally divided into two nuclei showing proliferation (white arrowheads); type II, condensed and fragmented nuclei showing apoptotic cells
(blue arrowheads); type III, condensed but not fragmented nuclei showing proliferation-arrested cells (yellow arrowheads). The cell numbers of each
type and the percentages to the total DsRed-positive cells are shown.
doi:10.1371/journal.pone.0018449.g002
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18449Figure 3. Peptide-based caspase inhibitor induces cell cycle arrest. HeLa cells were cultured in the presence of 0.6% DMSO, 300 mM Z-Asp-
CH2-DCB, or 0.1 mg/ml nocodazole for 25 hours, and cell cycle profiles were observed by flow cytometric analysis.
doi:10.1371/journal.pone.0018449.g003
Figure 4. Peptide-based caspase inhibitor impairs the transition from M to G1 phases through inhibiting APC/C. A) HeLa.S-Fucci cells
were cultured in the presence of 0.6% DMSO or 200 mM Z-Asp-CH2-DCB for 48 hours, and were observed with the time-lapse fluorescence
microscope at 30-minute intervals (see Videos S6 and S7). The morphology of cells and the color of cell nuclei at 0 and 48 hours are represented. Ten
mitotic cells with a round shape and a green color were randomly picked up from cells treated with DMSO (#1t o#10) and Z-Asp-CH2-DCB (#11 to
#20). B) The merged images of the mitotic cells (#11 to #20 in A) at 5 hours after treatment with Z-Asp-CH2-DCB were shown by phase contrast,
monomeric Azami-Green 1 (mAG1), and monomeric Kusabira-Orange 2 (mKO2) images, respectively.
doi:10.1371/journal.pone.0018449.g004
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there might be a possibility that the off-target effects of these
compounds on, for example, other cysteine proteases are
responsible for such inhibition [33,34]. It could be concluded,
however, that caspases such as caspase-3 and/or caspase-7 play a
critical role in cell proliferation by the following reasons; (1) lower
concentrations of the inhibitor specific to caspase-3 and -7
prevented cell proliferation (Figure 1B), (2) XIAP-BIR2, which is
an inhibitory protein specific for caspase-3 and -7 through a mode
of action different from that of the peptide-based inhibitors,
prevented cell proliferation (Figure 2), (3) knockdown of caspase-7
using siRNAs and shRNA resulted in the inhibition of cell
proliferation as well as cell cycle arrest at mitotic phase [22].
Although caspase-3 and -7 share a common substrate specificity
and the available inhibitors unfortunately do not distinguish these
two caspases, we speculate that the prevention of the cell cycle
progression at mitotic phase by the caspase inhibitors is mainly due
to the suppression of the caspase-7 activity because knockdown of
caspase-3 using siRNA had no significant effect on cell
proliferation [22].
Since caspase-3 and -7 are expressed as latent proenzymes, it is
important to elucidate how these caspases, especially caspase-7,
are activated during cell cycle. Caspase-8 and -9 are suggested to
function as upstream enzymes to cleave and activate caspase-3 and
-7 in apoptotic cells [1–3], and it is reasonable to ask whether the
caspase activation machinery in apoptosis is also involved in the
progression of cell cycle. Caspase-9, however, does not appear to
function as an upstream caspase for caspase-3 and -7 during the
cell cycle progression, because neither the peptide-based caspase-9
inhibitor nor XIAP-BIR3 prevented the cell proliferation
(Figure 1B and Figure 2). Caspase-8 may contribute to the cell
cycle regulation through activation of caspase-3 and/or caspase-7,
since the peptide-based caspase-8 inhibitor prevented, even
weakly, the cell proliferation (Figure 1B).
Caspase-3-/- mice are born in lower frequencies, and are
smaller in size than their littermates [35], whereas caspase-7-/-
mice are born without apparent abnormalities [36]. Double
knockout mice lacking both caspase-3 and -7 die immediately after
birth, although caspase-3/-7-deficient cells derived from the
double knockout mice can be cultured and proliferate in vitro
[36]. These results might suggest that caspase-3 and -7 are
important for survival but not essential for the cell proliferation or
cell cycle regulation. However, it has been reported that a
deficiency in caspase-3 can induce activation of caspase-6 and
caspase-7, and that in caspase-9 can enhance caspase-2 and
caspase-6 in knockout mice [37]. In addition, the depletion of
caspase-3 by siRNA induces a compensatory elevation in the
caspase-7 level [38]. Therefore, the cells deficient in caspase-3 and
-7 would not necessarily be expected to show an impairment of cell
proliferation because of the compensatory functions of other
caspases, that are not observed in the wild-type cells upon the
treatment with the inhibitors of caspase-3 and -7.
Among the eight mammalian IAPs, XIAP is the only IAP that is
a potent, direct inhibitor of the proteolytic activity of caspases and
is able to inhibit caspase-3 and caspase-7 with nanomolar activity.
Therefore, we tried to examine the effects of full length XIAP on
cell proliferation. However, the cells overexpressing XIAP resulted
in cell death during 24 hours’ observation (data not shown). Since
XIAP has multiple functions other than caspase inhibition, such as
ubiquitin-E3 and NEDD8-E3 ligases [4,5,39–41], it may be
essential for cell proliferation to maintain the protein level of XIAP
in cells. We showed that the BIR2 domain of XIAP fused to the
DsRed-monomer induced cell cycle arrest (Figure 2). Since this
system is artificial and the endogenous XIAP protein level was not
changed during cell cycle progression (data not shown), it is not
clear whether XIAP itself contributes to the cell cycle progression
through the inhibition of caspase activities. Although several lines
evidences suggested that XIAP is involved in the cell cycle
regulations at mitotic phase through the interaction with Chk1 and
the degradation of survivin [42,43], it is necessary to evaluate the
possible contribution of XIAP to the cell cycle regulation at mitotic
phase in relation to caspases.
Since activation of caspases by proteolytic cleavage is an
irreversible reaction, there are several mechanisms for inhibiting
spontaneous caspase activation to prevent apoptotic cell death
during cell cycle progression. IAPs such as cIAP1, cIAP2, and
XIAP function not only as caspase inhibitors but also as E3
ubiquitin ligases [4,5,39,40]. Recently, it was reported that XIAP
functions as a NEDD8-E3ligase for caspase-7 to prevent its
proteolytic activity [41]. Therefore, IAPs may function as
regulators for caspases during cell cycle progression by their
activities as caspase inhibitors and/or E3 ligases for ubiquitin and
NEDD8. Our data suggested that the transient activation of
caspase-3 and/or caspase-7 around mitotic phase. This activation
may be partially explained by the cell cycle-dependent relocaliza-
tion of IAPs such as cIAP1 that localized in nuclei during
interphase, late anaphase, and telophase while in the cytoplasm
early in mitosis [44].
Cell cycle is controlled by the ubiquitin-mediated proteolysis,
and the APC/C and SCF complexes function as E3 ligases that
mark a variety of proteins with ubiquitin in a cell cycle-dependent
manner [6]. The APC/C
Cdh1 complex is active in the late M and
G1 phases, and ubiquitinates various proteins such as Cdc20,
Cdh1, Aurora A, Aurora B, PLK1, and geminin, leading to their
proteolytic degradation [7,8]. The results described in Figures 4, 5,
and S1, in which the activities of not only APC/C
Cdh1 but also
APC/C
Cdc20 were impaired, may indicate that a failure occurred
in destruction of the cell cycle regulators in the caspase inhibitor-
Figure 5. Substrates for APC/C are accumulated in caspase
inhibitor-treated cells. HeLa.S-Fucci cells were cultured in the
presence of 0.6% DMSO or 200 mM Z-Asp-CH2-DCB for the indicated
times, and cells were harvested and lysates were subjected to
immunoblot analysis with the antibodies as indicated.
doi:10.1371/journal.pone.0018449.g005
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these abnormalities were caused by the broad-spectrum caspase
inhibitor, the subtype(s) of caspases contributing to the regulation
of APC/C is unclear. Caspase-7 may be the most probable
candidate, because shRNA specific for caspase-7 inhibited the
progression from M to G1 phases [22]. The identification of the
critical caspase-7 targets affecting the activities of APC/C and the
development of caspase-7 specific inhibitors will provide clues to
address these issues.
It was reported that caspases, including caspase-3, -7, -8, and -
9, are constitutively activated in some human tumor cells [19].
Consistently, we observed a critical role of caspases for cell
proliferation in HepG2, HeLa, and Jurkat cells in an apoptosis-
independent manner. On the other hand, many caspase
substrates that function in cell cycle checkpoints have been
identified, and dysfunction of these proteins has been suggested to
contribute to tumorigenesis [45–47]. For example, the Cdk
inhibitors p21 and p27, cyclin E, and Rb regulate the transition
of cell cycle from G1 to S phases, and Bub1, BubR1, Scc1/Rad
21, CENP-C, and INCENP are involved in the M phase
progression [48–50]. Therefore, caspases activated in tumor cells
may contribute to loss of cell cycle checkpoints and facilitate the
rapid proliferation of these tumor cells. Since we observed that
caspase inhibition induced cell cycle arrest at G2/M as well as G1
phases (Figure 3), caspase(s) may contribute to the cell cycle
regulation during G1 phase in addition to M phase. It is thus
interesting to evaluate a possible role of apoptosis-independent
caspase activation and the following cleavage of their substrates
during tumorigenesis.
Materials and Methods
Cell culture and transfection
HepG2 (a hepatocellular carcinoma line) and Jurkat (a
leukemia T-cell line) cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS). HeLa (a
cervical carcinoma line, clone D98AH2), HeLa-H2B-GFP [29]
and HeLa.S-Fucci [31] cells were cultured in DMEM
supplemented with 10% FBS. Transfection was performed
using FuGENE 6 (Roche). According to the manufacturer’s
instructions, we optimized transfection conditions such as the
ratio of the FuGENE 6 reagent to DNA and the incubation
time in the serum-free medium. In our transfection conditions,
we usually observed some apoptotic cells during the transfection
process, which may be induced by some stresses such as the
cytotoxicity of FuGENE 6 and the serum starvation. The
culture medium contained the final concentration of DMSO at
0.6%, when cells were treated with the reagents as indicated in
each experiments.
Cell proliferation assay
Cell proliferation reagent WST-1 (Roche) was used to monitor
cell viability according to the manufacturer’s instructions. In brief,
HepG2, HeLa, or Jurkat cells were plated in a 96-well plate at
4610
3,2 610
3,o r4 610
3 cells, respectively, per well with 100 ml
medium and incubated for 24 hours. After addition of caspase
inhibitors, Z-Asp-CH2-DCB (Peptide Institute), Boc-Asp(Obzl)-
CMK, and Ac-AAVALLPAVLLALLAP-DEVD-CHO, -LEHD-
CHO, and -IETD-CHO (Calbiochem), cells were incubated for
indicated days, followed by addition of WST-1 reagent to medium
and further incubation for 2 hours. The cleavage of the
tetrazolium salt WST-1 by mitochondrial dehydrogenases was
determined by measuring the absorbance at 450 nm with a
reference wavelength of 690 nm.
Plasmid construction
The XIAP cDNA fragment was amplified from a human
thymus cDNA library with the primers, 59-GCCTCGAGAGAT-
GACTTTTAACAGTTTT-39 and 59-GCGAATTCGATTAA-
GACATAAAAATTTT-39, and cloned into the XhoI-EcoRI site
of pBluescript SK(-) (Stratagene). The DNA sequence of the
isolated XIAP was confirmed by the dideoxy chain-termination
method. The fragments of XIAP-BIR2 with the linker region
(amino acids 124 to 237) and XIAP-BIR3 (amino acids 252 to 350)
were amplified with the primers, 59-GCCTCGAGGCAGAGAT-
CATTTTGCC-39 and 59-GCGAATTCTTAAATATTAAGA-
TTCCG-39, and 59-GCCTCGAGCAAATTCAACAAATCTT-
39 and 59-GCGAATTCTTACTCAAGTGAATGAGT-39, re-
spectively. The PCR method employing mutagenic oligonucleo-
tide primers was used to generate D148A/E219R/H223V
mutations in BIR2 and E314S mutation in BIR3. The resulting
fragments containing the wild type (Wt) and mutated XIAP-BIR2
with the linker region and XIAP-BIR3 were sequenced and cloned
into the XhoI-EcoRI site of pDsRed-Monomer-C1 (BD Biosciences)
to generate pDsRed-XIAP-BIR2-Wt, pDsRed-XIAP-BIR2-3M
containing D148A/E219R/H223V mutations, pDsRed-XIAP-
BIR3-Wt, and pDsRed-XIAP-BIR3-1M containing E314S muta-
tion, respectively.
Immunoblot analysis
Cells were lysed in lysis buffer [20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% Nonidet P-40, 50 mg/ml phenylmethane-
sulfonyl fluoride, 5 mM EDTA]. Protein samples were separat-
ed by SDS-polyacrylamide gel electrophoresis and blotted onto
Immobilon polyvinylidene difluoride membrane (Millipore).
Each protein was detected using primary antibodies as
indicated, horseradish peroxidase-conjugated secondary anti-
bodies, and ECL-plus detection reagent (GE Healthcare). Anti-
DsRed polyclonal antibody (8376-1) and anti-p27/Kip1 mono-
clonal antibody (554069) were obtained from BD Biosciences;
anti-Securin/PDS-1 monoclonal antibody (K0090-3), anti-
Cyclin B1 monoclonal antibody (K0128-3), anti-monomeric
Kusabira-Orange 2 polyclonal antibody (PM051), and anti-
monomeric Azami-Green 1 polyclonal antibody (PM052) were
from Medical & Biological Laboratories; anti-PLK1 rabbit
monoclonal antibody (#4513) was from Cell Signaling; anti-
cyclin E monoclonal antibody (sc-247) was from Santa Cruz
Biotechnology; anti-a-tubulin monoclonal antibody (T6074) was
from Sigma.
Time-lapse fluorescence microscopy
For time-lapse fluorescence microscopy, HeLa-H2B-GFP and
HeLa.S-Fucci cells were plated on a 35-mm glass bottom dish.
The medium was replaced with MEM supplemented with 10%
FBS without phenol red, and dishes were placed in a humidified
chamber at 37uC that was mounted on a fluorescence microscope
(model BZ-8000; Keyence) with a constant supply of mixed air
containing 5% CO2. Cells were observed and image data were
obtained automatically [22].
Flow cytometry
HeLa cells (1610
6 cells) were incubated with 0.5 ml of
propidium iodide/RNase buffer (BD Bioscience) after fixation
with 70% ethanol for 1 hour at -20uC, and DNA content was
measured using a FACSCaliber (Becton-Dickinson). 2610
4 events
were analyzed for each sample, and data were plotted using
Modifit software, and cell cycle profiles were determined by
CELLQuest (Becton-Dickinson).
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Figure S1 Progression of mitotic phase of HeLa.S-Fucci
cells treated without or with peptide-based caspase
inhibitor. HeLa.S-Fucci cells were cultured in the presence of
0.6% DMSO or 200 mM Z-Asp-CH2-DCB, and ten mitotic cells
with a round shape and a green color were randomly picked up
from cells treated with DMSO (#1t o#10) or Z-Asp-CH2-DCB
cells (#11 to #20) as described in Figure 4A. The progression of
the mitotic phase of each cell was observed with the time-lapse
fluorescence microscope at 30-minute intervals for 5 hours.
(TIF)
Video S1 Time-lapse observation of the effects of the
expression of DsRed-monomer. This video shows a typical
example of the effects of the expression of DsRed-monomer (red)
in HeLa-H2B-GFP cells in which chromatin is labeled with GFP
(green). Image data were obtained automatically every 15 minutes
for a period of 24 hours. The effects of DsRed-monomer
expression were summarized in Figure 2C (Quick Time;
0.65 MB).
(MOV)
Video S2 Time-lapse observation of the effects of the
expression of DsRed-XIAP-BIR2-Wt. This video shows a
typical example of the effects of the expression of DsRed-XIAP-
BIR2-Wt (red) in HeLa-H2B-GFP cells in which chromatin is
labeled with GFP (green). Image data were obtained automatically
every 15 minutes for a period of 24 hours. The effects of DsRed-
XIAP-BIR2-Wt expression were summarized in Figure 2C (Quick
Time; 0.86 MB).
(MOV)
Video S3 Time-lapse observation of the effects of the
expression of DsRed-XIAP-BIR2-3M. This video shows a
typical example of the effects of the expression of DsRed-XIAP-
BIR2-3M (red) in HeLa-H2B-GFP cells in which chromatin is
labeled with GFP (green). Image data were obtained automatically
every 15 minutes for a period of 24 hours. The effects of DsRed-
XIAP-BIR2-3M expression were summarized in Figure 2C (Quick
Time; 0.88 MB).
(MOV)
Video S4 Time-lapse observation of the effects of the
expression of DsRed-XIAP-BIR3-Wt. This video shows a
typical example of the effects of the expression of DsRed-XIAP-
BIR3-Wt (red) in HeLa-H2B-GFP cells in which chromatin is
labeled with GFP (green). Image data were obtained automatically
every 15 minutes for a period of 24 hours. The effects of DsRed-
XIAP-BIR3-Wt expression were summarized in Figure 2C (Quick
Time; 0.96 MB).
(MOV)
Video S5 Time-lapse observation of the effects of the
expression of DsRed-XIAP-BIR3-1M. This video shows a
typical example of the effects of the expression of DsRed-XIAP-
BIR3-1M (red) in HeLa-H2B-GFP cells in which chromatin is
labeled with GFP (green). Image data were obtained automatically
every 15 minutes for a period of 24 hours. The effects of DsRed-
XIAP-BIR3-1M expression were summarized in Figure 2C.
(Quick Time; 0.94 MB)
(MOV)
Video S6 Time-lapse observation of the effects of 0.6%
DMSO in cell culture. This video shows the culture of HeLa.S-
Fucci cells in the presence of 0.6% DMSO. Image data were
obtained automatically every 30 minutes for a period of 48 hours.
The time course of the video indicates that 0.6% of DMSO did
not have a significant effect on cell proliferation of HeLa.S-Fucci
cells as described in Figures 4 and S1. (Quick Time; 1.9 MB)
(MOV)
Video S7 Time-lapse observation of the effects of the
caspase inhibitor in cell culture. This video shows the effects
of 200 mM Z-Asp-CH2-DCB on the morphology of cells and color
of cell nuclei (green and orange) of HeLa.S-Fucci cells. Image data
were obtained automatically every 30 minutes for a period of
48 hours. The effects of the caspase inhibitor were described in
Figures 4 and S1. (Quick Time; 1.3 MB)
(MOV)
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